GSK drug Seretide/Advair global revenue by region 2022

This statistic depicts the global revenue of Seretide/Advair around the world from 2012 to 2022, by region. In 2022, Seretide/Advair generated a revenue of 308 million British pounds in the United States. Advair is the brand name marketed in the U.S. and Canada but is known as Seretide in many other countries. This pharmaceutical product is used to treat asthma through a combination of a preventer inhaler and a symptom controller.

Revenue of GSK's Seretide/Advair worldwide from 2012 to 2022, by region (in million British pounds)

Characteristic	Total	United States	Europe	Emerging markets	Rest of world/international
2022	1,159	308	287	-	564
2021	1,357	486	322	-	549
2020	1,535	434	449	-	652
2019	1,730	502	502	-	726
2018	2,422	1,097	599	-	726
2017	3,130	1,610	736	-	784
2016	3,485	1,829	835	-	821
2015*	3,681	1,865	1,014	-	802
2014	4,229	1,972	1,330	400	527
2013	5,274	2,769	1,458	429	618
2012	5,046	2,533	1,447	417	649

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

March 2023

More information

Region

Worldwide

Survey time period

2012 to 2022

Supplementary notes

This statistic was assembled from several editions of GSK's annual report.
* From 2015 on, all other countries except the United States and European countries are included in "rest of world/international".

Citation formats